BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 15, 2002
 |  BioCentury  |  Politics, Policy & Law

EC pharmaceutical regulatory reform plan

EU Commissioner Erkki Liikanen last week outlined the Commission's plans for reform of the EU's pharmaceutical legislation. The Commission's key proposals are the introduction of fast-track registration, conditional marketing authorization, and removal of the marketing authorization renewal procedure. For patients, the Commission wants to provide more transparency and access to data on the Internet.

In a speech before the Mentor Group Forum for U.S.-EU Legal-Economic Affairs, Liikanen said the Commission's objective was to continue to guarantee a high level of health protection, to ensure access to high quality medicines, and to rationalize and simplify the regulatory process, while making it more transparent for both companies and patients.

To increase and accelerate the availability of innovative medicines, Liikanen said the Commission planned to "reduce...

Read the full 600 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >